Laboratory Assessment of Direct Oral Anticoagulants

被引:70
|
作者
Douxfils, Jonathan [1 ]
Gosselin, Robert C. [2 ]
机构
[1] Univ Namur, Namur Res Inst Life Sci, Namur Thrombosis & Hemostasis Ctr, Dept Pharm, Namur, Belgium
[2] Univ Calif, Davis Hlth Syst, Sacramento, CA USA
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2017年 / 43卷 / 03期
关键词
apixaban; dabigatran; edoxaban; rivaroxaban; prothrombin time; activated partial thromboplastin time; dilute thrombin time; Ecarin; anti-Xa; FACTOR-XA INHIBITOR; DIRECT THROMBIN INHIBITOR; MAJOR BLEEDING COMPLICATIONS; TANDEM MASS-SPECTROMETRY; LONG-TERM TREATMENT; PERFORMANCE LIQUID-CHROMATOGRAPHY; NONVALVULAR ATRIAL-FIBRILLATION; PERIOPERATIVE HEMOSTASIS GIHP; COAGULATION ASSAYS; VENOUS THROMBOEMBOLISM;
D O I
10.1055/s-0036-1597296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable pharmacokinetic and food impact of warfarin, episodic monitoring is required. Since the early 2000s, direct oral anticoagulants (DOACs) entered into clinical trials as a potential alternative strategy to oral vitamin K antagonists for long-term anticoagulation. As these drugs have predictable pharmacokinetics and pharmacodynamics, there was no requirement for episodic or routine monitoring. However, shortly after their introduction into clinical use, it became apparent that certain emergent or acute situations may require some capacity to measure these drugs, especially in a bleeding patient with DOAC exposure. The scramble for literature and data to support or suggest laboratory methods which can rapidly and accurately quantify or estimate DOAC concentration soon began. This review describes the literature to date, and recommendations for laboratories to provide tests that will assure either the presence/absence of DOAC or the capacity to quantify DOAC using rapid methods that could be implemented on most clinical laboratory instruments.
引用
收藏
页码:277 / 290
页数:14
相关论文
共 50 条
  • [1] Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
    Samuelson, Bethany T.
    Cuker, Adam
    Siegal, Deborah M.
    Crowther, Mark
    Garcia, David A.
    [J]. CHEST, 2017, 151 (01) : 127 - 138
  • [2] An update on laboratory assessment for direct oral anticoagulants (DOACs)
    Gosselin, Robert C.
    Adcock, Dorothy M.
    Douxfils, Jonathan
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 : 33 - 39
  • [3] The laboratory and the direct oral anticoagulants
    Tripodi, Armando
    [J]. BLOOD, 2013, 121 (20) : 4032 - 4035
  • [4] Laboratory assessment of the direct oral anticoagulants: who can benefit?
    Akpan, Imo J.
    Cuker, Adam
    [J]. KARDIOLOGIA POLSKA, 2021, 79 (06) : 622 - 630
  • [5] Direct oral anticoagulants - laboratory monitoring
    Spannagl, M.
    [J]. PHLEBOLOGIE, 2014, 43 (05) : 232 - 236
  • [6] Laboratory measurement of the direct oral anticoagulants
    Dale, Brian J.
    Chan, Noel C.
    Eikelboom, John W.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (03) : 315 - 336
  • [7] Assessing Direct Oral Anticoagulants in the Clinical Laboratory
    Gosselin, Robert C.
    Cuker, Adam
    [J]. CLINICS IN LABORATORY MEDICINE, 2024, 44 (03) : 551 - 562
  • [8] Challenges to Laboratory Monitoring of Direct Oral Anticoagulants
    Qiao, Jesse
    Tran, Minh-Ha
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [9] Direct Oral Anticoagulants: Laboratory Challenges and Antidotes
    Beyer-Westendorf, Jan
    Koehler, Christina
    [J]. HAMOSTASEOLOGIE, 2023, 43 (01): : 37 - 43
  • [10] Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
    Dunois, Claire
    [J]. BIOMEDICINES, 2021, 9 (05)